Repligen Corp
NASDAQ:RGEN
Operating Margin
Repligen Corp
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Repligen Corp
NASDAQ:RGEN
|
6.7B USD |
3%
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD |
15%
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
178.3B USD |
18%
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
142.1B USD |
22%
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
71.2T KRW |
32%
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
39.9B CHF |
18%
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
33.9B USD |
23%
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
242.8B CNY |
27%
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
33.7B USD |
15%
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26.1B USD |
29%
|
|
| IN |
|
Divi's Laboratories Ltd
NSE:DIVISLAB
|
1.8T INR |
28%
|
Repligen Corp
Glance View
Repligen Corporation has carved a niche for itself in the dynamic world of bioprocessing, a sector that fuels the global production of biologic drugs. At its core, Repligen specializes in providing innovative technologies and solutions that enhance the efficiency and productivity of manufacturing processes for advanced therapeutics, ranging from monoclonal antibodies to cell and gene therapies. The company operates primarily through its product categories, which include filtration, chromatography, and analytics, bridging the gaps in the biomanufacturing process. By focusing on these critical yet underserved areas, Repligen has positioned itself as a pivotal player enabling pharmaceutical and biotech firms to streamline their production lines, reduce costs, and meet the increasing demand for life-saving biologics. What sets Repligen apart is its strategic approach to generating revenue by staying ahead of industry trends and continuously innovating its product offerings. As biopharmaceutical production shifts towards more personalized and complex therapies, Repligen adeptly supplies the tools and systems required to tackle these challenging demands. The company's revenue model revolves around the sale of its proprietary products, which are essential components in biopharmaceutical manufacturing. By forging strong relationships with industry leaders and consistently delivering high-quality, reliable solutions, Repligen ensures a steady stream of business, leveraging its technological prowess to capture and sustain market share. Through this combination of strategic foresight and steadfast execution, Repligen continues to bolster its reputation as an indispensable ally to the world's leading biotech firms.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Repligen Corp's most recent financial statements, the company has Operating Margin of 2.6%.
You don't have any saved screeners yet